Table 1 Baseline characteristics of participating subjects with (n = 55) and without (n = 30) maximal oxygen uptake measurements before and six months after start of adjuvant cancer treatment. Results are presented as frequencies and percentages in parenthesis unless otherwise stated*
|  | Baseline and follow up n = 55 (64.7) | Baseline only n = 30 (35.3) |
|---|---|---|
Age yrs., mean (SD) | 58.8 (11.1) | 59.2 (12.9) |
Height cm, mean (SD) | 168 (7.7) | 167 (5.6)a |
Weight kg, mean (SD) | 74.3 (14) | 75.2 (16)a |
Females, n (%) | 42 (80.8)b | 27 (90) |
Cohabitation | b | Â |
 Married/cohabitant, n (%) | 42 (80.8) | 21 (70) |
 One couple, two households, n (%) | 3 (5.8) | 3 (10) |
 Living alone, n (%) | 7 (13.5) | 6 (20) |
Education level, n (%) | c | Â |
 Compulsory school, n (%) | 4 (7.8) | 4 (13.3) |
 High School, n (%) | 17 (33.3) | 8 (26.7) |
 College/university n (%) | 30 (58.8) | 18 (60) |
Working status | b | Â |
 Full time work, n (%) | 15 (28.8) | 6 (20) |
 Part time work, n (%) | 6 (11.5) | 3 (10) |
 Retired, Homemaker n (%) | 20 (38.5) | 12 (40) |
 Sick leave, n (%) | 11 (21.2) | 9 (30) |
Diagnosis | ||
 Breast cancer, n (%) | 45 (81.8) | 26 (86.7) |
 Prostate cancer, n (%) | 8 (14.5) | 2 (6.7) |
 Colorectal cancer, n (%) | 2 (3.6) | 2 (6.7) |
Primary adjuvant treatment | ||
 Chemotherapy, n (%) | 20 (36.4) | 14 (46.7) |
 Type chemotherapyd | ||
  Docetaxcel + FEC low-dose | 9 (45.0) |  |
  Docetaxcel + FEC high-dose | 8 (40.0) |  |
  CAPOX | 1 (5.0) |  |
  Capecitabine single | 1 (5.0) |  |
 Radiation therapy, n (%) | 18 (32.7) | 10 (33.3) |
 Endocrine treatment, n (%) | 17 (30.9) | 6 (20) |
Physical fatigue, n (%) | 47 (94)e | 28 (93.3) |
MVPA (SD)* (min.day−1) | 47.6 (30.1)f | 33.3 (19.5)g |